This prospective cohort study aims to investigate the association between prenatal blood levels of Emerging Contaminants and the five-year incidence of atopic dermatitis (AD) in offspring.
This prospective birth cohort study, conducted within the Shanghai prenatal population, involves the collection of maternal blood samples during gestation to directly measure the biological exposure levels of Emerging Contaminants, including Per- and Polyfluoroalkyl Substances (PFAS), Organophosphate Flame Retardants (OPFRs), and Microplastics. Serum and whole blood levels of these contaminants are evaluated during pregnancy at 12-14, 22-26, and 31-34 gestational weeks. Subsequently, the study assesses skin barrier function in infants at 24-48 hours, 42 days, and 6 months of age. During a five-year period, the occurrence of atopic dermatitis (AD) in offspring is assessed. The objectives of this cohort study are twofold: (1) to elucidate the relationship between maternal exposure to Emerging Contaminants and the development of AD in offspring, and (2) to evaluate the impact of such exposure on the skin barrier function of infants. This research aims to provide substantial evidence for the prevention of AD, offering a unique and meaningful approach to mitigating the incidence of AD.
Study Type
OBSERVATIONAL
Enrollment
456
Levels of Emerging Contaminants (ECs), such as Per- and Polyfluoroalkyl Substances (PFASs), Organophosphate Flame Retardants (OPFRs), and Microplastics, are assessed in maternal blood and umbilical cord blood during gestation.
Children Hospital of Fudan University
Shanghai, Shanghai Municipality, China
atopic dermatitis: Infant atopic dermatitis incidence
Disease diagnosis according to the criteria of Williams. Skin status was examined via onsite interview by pediatric dermatologists. Parents consulted or visited a dermatologist once their baby developed any skin symptoms.
Time frame: at 1 year old
atopic dermatitis
Disease diagnosis according to the criteria of Williams. Skin status was examined via onsite interview by pediatric dermatologists. Parents consulted or visited a dermatologist once their baby developed any skin symptoms.
Time frame: incidence of AD during 6 months after birth
atopic dermatitis
Disease diagnosis according to the criteria of Williams. Skin status was examined via onsite interview by pediatric dermatologists. Parents consulted or visited a dermatologist once their baby developed any skin symptoms.
Time frame: incidence of AD at the age of two.
atopic dermatitis
Disease diagnosis according to the criteria of Williams. Skin status was examined via onsite interview by pediatric dermatologists. Parents consulted or visited a dermatologist once their baby developed any skin symptoms.
Time frame: incidence of AD at the age of five.
prenatal exposure to Perfluoroalkyl and Polyfluoroalkyl Substances (PFASs) at early pregnancy
Maternal whole blood levels of Perfluoroalkyl and Polyfluoroalkyl Substances (PFASs) comprising 15 variants: PFPeA, PFHxA, PFHpA, PFOA, PFNA, PFDA, PFUnDA, PFDoDA, PFTrDA, PFHpDA, PFBS, PFPeS, PFHxS, PFOS, and PFDS
Time frame: 12-14 gestational weeks
prenatal exposure to Perfluoroalkyl and Polyfluoroalkyl Substances (PFASs) at mid pregnancy
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Maternal whole blood levels of Perfluoroalkyl and Polyfluoroalkyl Substances (PFASs) comprising 15 variants: PFPeA, PFHxA, PFHpA, PFOA, PFNA, PFDA, PFUnDA, PFDoDA, PFTrDA, PFHpDA, PFBS, PFPeS, PFHxS, PFOS, and PFDS
Time frame: 22-26 gestational weeks
prenatal exposure to Perfluoroalkyl and Polyfluoroalkyl Substances (PFASs) at late pregnancy
Maternal whole blood levels of Perfluoroalkyl and Polyfluoroalkyl Substances (PFASs) comprising 15 variants: PFPeA, PFHxA, PFHpA, PFOA, PFNA, PFDA, PFUnDA, PFDoDA, PFTrDA, PFHpDA, PFBS, PFPeS, PFHxS, PFOS, and PFDS
Time frame: 34-36 gestational weeks
prenatal exposure to Perfluoroalkyl and Polyfluoroalkyl Substances (PFASs) at first trimester
Maternal serum levels of Perfluoroalkyl and Polyfluoroalkyl Substances (PFASs) comprising 15 variants: PFPeA, PFHxA, PFHpA, PFOA, PFNA, PFDA, PFUnDA, PFDoDA, PFTrDA, PFHpDA, PFBS, PFPeS, PFHxS, PFOS, and PFDS
Time frame: 12-14 gestational weeks
prenatal exposure to Perfluoroalkyl and Polyfluoroalkyl Substances (PFASs) at second trimester
Maternal serum levels of Perfluoroalkyl and Polyfluoroalkyl Substances (PFASs) comprising 15 variants: PFPeA, PFHxA, PFHpA, PFOA, PFNA, PFDA, PFUnDA, PFDoDA, PFTrDA, PFHpDA, PFBS, PFPeS, PFHxS, PFOS, and PFDS
Time frame: 22-26 gestational weeks
prenatal exposure to Perfluoroalkyl and Polyfluoroalkyl Substances (PFASs) at third trimester
Maternal serum levels of Perfluoroalkyl and Polyfluoroalkyl Substances (PFASs) comprising 15 variants: PFPeA, PFHxA, PFHpA, PFOA, PFNA, PFDA, PFUnDA, PFDoDA, PFTrDA, PFHpDA, PFBS, PFPeS, PFHxS, PFOS, and PFDS
Time frame: 34-36 gestational weeks
Perfluoroalkyl and Polyfluoroalkyl Substances (PFASs) in Umbilical cord whole blood
Umbilical cord whole blood levels of PFDoDA, PFTrDA, PFHpDA, PFBS, PFPeS, PFHxS, PFOS, and PFDS
Time frame: at delivery
Umbilical cord serum Perfluoroalkyl and Polyfluoroalkyl Substances (PFASs)
Umbilical cord serum levels of PFDoDA, PFTrDA, PFHpDA, PFBS, PFPeS, PFHxS, PFOS, and PFDS
Time frame: at delivery.
prenatal exposure to Organophosphate Flame Retardants (OPFRs) at early pregnancy
Maternal whole blood levels of Organophosphate Flame Retardants (OPFRs) comprising 9 variants: TEP、TBP、TBEP/TBOEP、TPrP、TCEP、TCPP/TCIPP、TDCPP/TDCIPP、TDBP/TDBPP、TPhP/TPHP
Time frame: 12-14 gestational weeks
prenatal exposure to Organophosphate Flame Retardants (OPFRs) at mid pregnancy
Maternal whole blood levels of Organophosphate Flame Retardants (OPFRs) comprising 9 variants: TEP、TBP、TBEP/TBOEP、TPrP、TCEP、TCPP/TCIPP、TDCPP/TDCIPP、TDBP/TDBPP、TPhP/TPHP
Time frame: 22-26 gestational weeks
prenatal exposure to Organophosphate Flame Retardants (OPFRs) at late pregnancy
Maternal whole blood levels of Organophosphate Flame Retardants (OPFRs) comprising 9 variants: TEP、TBP、TBEP/TBOEP、TPrP、TCEP、TCPP/TCIPP、TDCPP/TDCIPP、TDBP/TDBPP、TPhP/TPHP
Time frame: 34-36 gestational weeks
prenatal exposure to Organophosphate Flame Retardants (OPFRs) at first trimester
Maternal serum levels of Organophosphate Flame Retardants (OPFRs) comprising 9 variants: TEP、TBP、TBEP/TBOEP、TPrP、TCEP、TCPP/TCIPP、TDCPP/TDCIPP、TDBP/TDBPP、TPhP/TPHP
Time frame: 12-14 gestational weeks
prenatal exposure to Organophosphate Flame Retardants (OPFRs) at second trimester
Maternal serum levels of Organophosphate Flame Retardants (OPFRs) comprising 9 variants: TEP、TBP、TBEP/TBOEP、TPrP、TCEP、TCPP/TCIPP、TDCPP/TDCIPP、TDBP/TDBPP、TPhP/TPHP
Time frame: 22-26 gestational weeks
prenatal exposure to Organophosphate Flame Retardants (OPFRs) at third trimester
Maternal serum levels of Organophosphate Flame Retardants (OPFRs) comprising 9 variants: TEP、TBP、TBEP/TBOEP、TPrP、TCEP、TCPP/TCIPP、TDCPP/TDCIPP、TDBP/TDBPP、TPhP/TPHP
Time frame: 34-36 gestational weeks
Organophosphate Flame Retardants (OPFRs) in Umbilical cord whole blood
Umbilical cord whole blood levels of PFDoDA, PFTrDA, PFHpDA, PFBS, PFPeS, PFHxS, PFOS, and PFDS
Time frame: at delivery
Umbilical cord serum Organophosphate Flame Retardants (OPFRs)
Umbilical cord serum levels of PFDoDA, PFTrDA, PFHpDA, PFBS, PFPeS, PFHxS, PFOS, and PFDS
Time frame: at delivery
Infant skin barrier function (Transepidermal Water Loss, TEWL）
TEWL will be evaluated by the device of Multi Probe Adapter 4.
Time frame: infant 24-48 hours
Infant skin barrier function (Transepidermal Water Loss, TEWL）
TEWL will be evaluated by the device of Multi Probe Adapter 4.
Time frame: infant 42 days old
Infant skin barrier function (Transepidermal Water Loss, TEWL）
TEWL will be evaluated by the device of Multi Probe Adapter 4.
Time frame: infant 6 months old
Infant skin barrier function (Stratum corneum hydration, SCH)
SCH will be evaluated by the device of Multi Probe Adapter 4.
Time frame: infant 24-48 hours
Infant skin barrier function (Stratum corneum hydration, SCH)
SCH will be evaluated by the device of Multi Probe Adapter 4.
Time frame: infant 42 days old
Infant skin barrier function (Stratum corneum hydration, SCH)
SCH will be evaluated by the device of Multi Probe Adapter 4.
Time frame: infant 6 months old
Infant skin barrier function (sebum content)
Sebum content will be evaluated by the device of Multi Probe Adapter 4.
Time frame: infant 24-48 hours
Infant skin barrier function (sebum content)
Sebum content will be evaluated by the device of Multi Probe Adapter 4.
Time frame: infant 42 days old
Infant skin barrier function (sebum content)
Sebum content will be evaluated by the device of Multi Probe Adapter 4.
Time frame: infant 6 months old
Infant skin barrier function (skin surface pH)
Skin pH will be evaluated by the device of Multi Probe Adapter 4.
Time frame: infant 24-48 hours
Infant skin barrier function (skin surface pH)
Skin pH will be evaluated by the device of Multi Probe Adapter 4.
Time frame: infant 42 days old
Infant skin barrier function (skin surface pH)
Skin pH will be evaluated by the device of Multi Probe Adapter 4.
Time frame: infant 6 months old
prenatal exposure to Microplastics at early pregnancy
Maternal whole blood levels of Microplastics
Time frame: 12-14 gestational weeks
prenatal exposure to Microplastics at mid pregnancy
Maternal whole blood levels of Microplastics
Time frame: 22-26 gestational weeks
prenatal exposure to Microplastics at late pregnancy
Maternal whole blood levels of Microplastics
Time frame: 34-36 gestational weeks
prenatal exposure to Microplastics at first trimester
Maternal serum levels of Microplastics
Time frame: 12-14 gestational weeks
prenatal exposure to Microplastics at second trimester
Maternal serum levels of Microplastics
Time frame: 22-26 gestational weeks
prenatal exposure to Microplastics at third trimester
Maternal serum levels of Microplastics
Time frame: 34-36 gestational weeks
Microplastics in Umbilical cord whole blood
Umbilical cord whole blood levels of Microplastics
Time frame: at delivery.
Umbilical cord serum Microplastics
Umbilical cord serum levels of Microplastics
Time frame: at delivery.
Allergic rhinitis
An inquiry into the patient's medical history and electronic medical record
Time frame: incidence of allergic rhinitis at the age of five.
Asthma
An inquiry into the patient's medical history and electronic medical record
Time frame: incidence of asthma at the age of five.
Infantile hemangioma
Diagnosed by dermatologists
Time frame: incidence of Infantile hemangioma at 1 year old